Place and Date of
Birth: Bologna, Italy 14
June 1964
Work
address: Servizio di
Semeiotica Medica, Via Massarenti 9, 40138 Bologna, Italy
Phone:
+390516362928; Fax: +390516362930; e-mail: maurizio.biselli@unibo.it
Academic
Curriculum
ClassicHigh
SchoolDegree :
1983, Liceo
Classico G. Galvani, Bologna, Italy
Degree in
Medicine: March
31, 1994, University of
Bologna, Italy
Board Certified in
Geriatric medicine: November 10,
1999, University of
Bologna, Italy
Doctors Degree in
Fisiologia Applicata e Fisiopatologia: March 19,
2003, University of
Bologna, Italy
Area of
interest
Liver
diseases
Clinical
Experience
From June 1994 to
September 1996 Dr Biselli had taken care patients with
hepatocellular carcinoma.
From July 1995 he
takes care patients listed for liver transplantation or yet
transplanted.
From October 2000
to March 2002 Dr Biselli worked in the outpatient's activity of the
Center for Dementia of Azienda U.S.L. Città di Bologna, Bologna, Italy.
From April 2002 to
October 2006 Dr Biselli works in the outpatient's activity of the
Ambulatorio di Epatologia of Presidio Ospedaliero Paola
(Cosenza),
Azienda Sanitaria n° 1, Regione
Calabria, Italy.
From November 2006
Dr Biselli works as Assistant Professor in the Operative Unit of
Semeiotica Medica – Dipartimento di Scienze Mediche e
Chirurgiche, University
of Bologna.
Area of
research
1. Clinical trials
with antiviral and/or immunomodulatory drugs
2. Liver
transplantation: prevention and treatment of HBV or HCV
reinfection, waiting list management, alcoholic cirrhosis, clinical
complications after liver transplantation
3. Chronic
hepatitis B: pathogenesis and treatment
4. Chronic
hepatitis C: pathogenesis and treatment
5. Clinical trials
in patients with hepatocellular carcinoma
Previous studies
conducted
- A phase II
randomized multicenter, multinational open-label study to evaluate
the efficacy and safety of pegylated interferon alpha plus
ribavirin vs pegylated interferon alpha plus ribavirin plus
histamine dihydrochloride injection in patients with chronic
hepatitis C virus infection who have previously not responded to
interferon plus ribavirin combination therapy.MP-8899-0406. Sponsor : Maxim Pharmaceuticals, Inc. Ethics committee Approved 21.01.2003 - N.Protocol 8/2003/O
- SIROLIMUS protocol 0468H1-313: A Randomized, Open-label, Comparative Evaluation Of Conversion From Calcineurin Inhibitor Treatment To Sirolimus Treatment Versus Continuation Of Calcineurin Inhibitor Treatment In Liver Allograft recipients Undergoing Maintenance Therapy.
- Study KB036: Studio multicentrico, in aperto, di fase II per valutare la farmacocinetica di VENBIG (immunoglobulina umana anti-epatite B per uso endovenoso) e IMMUNOHBS (immunoglobulina umana anti-epatite B per uso intramuscolare) in pazienti trapiantati di fegato HBsAg negativi. Valutazione di sicurezza ed efficacia del trattamento con IMMUNOHBS in tutti i pazienti arruolati per lo studio di farmacocinetica. Kedrion SpA, 55020 Castelvecchio Pascoli (Lucca), Italia. CODICE EUDRACT: 2005-000840-10.
- EU H2020 - CARBALIVE: Clinical evaluation of carbons of controlled porosity as a new therapeutic for the treatment of liver cirrhosis and non-alcoholic fatty liver disease.
- EU H2020 - LIVERHOPE: Simvastatin and Rifaximin as new therapy for patients with decompensated cirrhosis.
- EU H2020 - DECISION: DEcompensated CIrrhoSIs: identification of new cOmbiNatorial therapies based on systems approaches.
Scientific
association Membership
Italian
Association for the Study of the Liver
Actual
Position
Assistant
Professor
Papers with impact factor 73.
